Clinical Trial: Intravitreal Bevacizumab for Neovascular Glaucoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial
Brief Summary: Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
Detailed Summary:
Sponsor: Shahid Beheshti University of Medical Sciences
Current Primary Outcome:
- Change in intraocular pressure [ Time Frame: 6 months ]
- Change in extent of iris neovascularization [ Time Frame: 6 months ]
Original Primary Outcome:
Current Secondary Outcome: Best corrected visual acuity [ Time Frame: 6 months ]
Original Secondary Outcome:
Information By: Shahid Beheshti University of Medical Sciences
Dates:
Date Received: October 4, 2006
Date Started: April 2006
Date Completion:
Last Updated: February 14, 2008
Last Verified: February 2008
